{
  "url": "https://openlegislation.uk/eu-regulation-2014-605/annex-III",
  "json_url": "https://openlegislation.uk/eu-regulation-2014-605/annex-III.json",
  "legislation": "eur/2014/605",
  "legislation_title": "Commission Regulation (EU) No 605/2014 of 5 June 2014 amending, for the purposes of introducing hazard and precautionary statements in the Croatian language and its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2014-605",
  "path": "annex/III",
  "kind": "annex",
  "number": "III",
  "heading": null,
  "text": "Part 3 of Annex VI is amended as follows:\n(1) Table 3.1 is amended as follows:\n(a) the entry corresponding to index number 015-188-00-X is deleted;\n(b) the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 and 616-035-00-5 are replaced by the following corresponding entries:\n‘\n006-086-00-6\nfenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate\n276-696-7\n72490-01-8\nCarc. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH410\nM = 1\nM = 10 000\n015-154-00-4\nethephon; 2-chloroethylphosphonic acid\n240-718-3\n16672-87-0\nAcute Tox. 3\nAcute Tox. 4\nAcute Tox. 4\nSkin Corr. 1C\nAquatic Chronic 2\nH311\nH332\nH302\nH314\nH411\nGHS06\nGHS05\nGHS09\nDgr\nH311\nH332\nH302\nH314\nH411\nEUH071\n015-192-00-1\ntetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate\n432-770-2\n139189-30-3\nSkin Sens. 1\nH317\nGHS07\nWng\nH317\n601-023-00-4\nethylbenzene\n202-849-4\n100-41-4\nFlam. Liq. 2\nAcute Tox. 4*\nSTOT RE 2\nAsp. Tox. 1\nH225\nH332\nH373 (hearing organs)\nH304\nGHS02\nGHS07\nGHS08\nDgr\nH225\nH332\nH373 (hearing organs)\nH304\n601-026-00-0\nstyrene\n202-851-5\n100-42-5\nFlam. Liq. 3\nRepr. 2\nAcute Tox. 4*\nSTOT RE 1\nSkin Irrit. 2\nEye Irrit. 2\nH226\nH361d\nH332\nH372 (hearing organs)\nH315\nH319\nGHS02\nGHS08\nGHS07\nDgr\nH226\nH361d\nH332\nH372 (hearing organs)\nH315\nH319\n*\nD\n603-061-00-7\ntetrahydro-2-furylmethanol;\ntetrahydrofurfuryl alcohol\n202-625-6\n97-99-4\nRepr. 1B\nEye Irrit. 2\nH360Df\nH319\nGHS08\nGHS07\nDgr\nH360Df\nH319\n605-001-00-5\nformaldehyde …%\n200-001-8\n50-00-0\nCarc. 1B\nMuta. 2\nAcute Tox. 3*\nAcute Tox. 3*\nAcute Tox. 3*\nSkin Corr. 1B\nSkin Sens. 1\nH350\nH341\nH301\nH311\nH331\nH314\nH317\nGHS08\nGHS06\nGHS05\nDgr\nH350\nH341\nH301\nH311\nH331\nH314\nH317\n*\nSkin Corr. 1B; H314: C ≥ 25 %\nSkin Irrit. 2; H315: 5 % ≤ C < 25 %\nEye Irrit. 2; H319: 5 % ≤ C < 25 %\nSTOT SE 3; H335: C ≥ 5 %\nSkin Sens. 1; H317: C ≥ 0,2 %\nB, D\n605-008-00-3\nacrolein;\nprop-2-enal;\nacrylaldehyde\n203-453-4\n107-02-8\nFlam. Liq. 2\nAcute Tox. 1\nAcute Tox. 2\nAcute Tox. 3\nSkin Corr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH225\nH330\nH300\nH311\nH314\nH400\nH410\nGHS02\nGHS06\nGHS05\nGHS09\nDgr\nH225\nH330\nH300\nH311\nH314\nH410\nEUH071\nSkin Corr. 1B;\nH314: C ≥ 0,1 %\nM = 100\nM = 1\nD\n616-035-00-5\ncymoxanil (ISO);\n2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide\n261-043-0\n57966-95-7\nRepr. 2\nAcute Tox. 4\nSTOT RE 2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH361fd\nH302\nH373 (blood, thymus)\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361fd\nH302\nH373 (blood, thymus)\nH317\nH410\nM = 1\nM = 1\n’\n(c) the following entries are inserted in accordance with the order of the entries set out in Table 3.1:\n‘\n050-028-00-2\n2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n260-829-0\n57583-35-4\nRepr. 2\nAcute Tox. 4\nSTOT RE 1\nSkin Sens. 1A\nH361d\nH302\nH372 (nervous system, immune system)\nH317\nGHS08\nGHS07\nDgr\nH361d\nH302\nH372 (nervous system, immune system)\nH317\n050-029-00-8\ndimethyltin dichloride\n212-039-2\n753-73-1\nRepr. 2\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 3\nSTOT RE 1\nSkin Corr. 1B\nH361d\nH330\nH301\nH311\nH372 (nervous system, immune system)\nH314\nGHS08\nGHS06\nGHS05\nDgr\nH361d\nH330\nH301\nH311\nH372 (nervous system, immune system)\nH314\nEUH071\n601-088-00-9\n4-vinylcyclohexene\n202-848-9\n100-40-3\nCarc. 2\nH351\nGHS08\nWng\nH351\n601-089-00-4\nmuscalure; cis-tricos-9-ene\n248-505-7\n27519-02-4\nSkin Sens. 1B\nH317\nGHS07\nWng\nH317\n604-090-00-8\n4-tert-butylphenol\n202-679-0\n98-54-4\nRepr. 2\nSkin Irrit. 2\nEye Dam. 1\nH361f\nH315\nH318\nGHS08\nGHS05\nDgr\nH361f\nH315\nH318\n604-091-00-3\netofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether\n407-980-2\n80844-07-1\nLact.\nAquatic Acute 1\nAquatic Chronic 1\nH362\nH400\nH410\nGHS09\nWng\nH362\nH410\nM = 100\nM = 1 000\n606-146-00-7\ntralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one\n-\n87820-88-0\nCarc. 2\nAcute Tox. 4\nAquatic Chronic 2\nH351\nH302\nH411\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH411\n606-147-00-2\ncycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one\n405-230-9\n101205-02-1\nRepr. 2\nH361d\nGHS08\nWng\nH361d\n607-705-00-8\nbenzoic acid\n200-618-2\n65-85-0\nSTOT RE 1\nSkin Irrit. 2\nEye Dam. 1\nH372 (lungs) (inhalation)\nH315\nH318\nGHS08\nGHS05\nDgr\nH372 (lungs) (inhalation)\nH315\nH318\n607-706-00-3\nmethyl 2,5-dichlorobenzoate\n220-815-7\n2905-69-3\nAcute Tox. 4\nSTOT SE 3\nAquatic Chronic 2\nH302\nH336\nH411\nGHS07\nGHS09\nWng\nH302\nH336\nH411\n612-287-00-5\nfluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine\n-\n79622-59-6\nRepr. 2\nAcute Tox. 4\nEye Dam. 1\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH332\nH318\nH317\nH400\nH410\nGHS08\nGHS07\nGHS05\nGHS09\nDgr\nH361d\nH332\nH318\nH317\nH410\nM = 10\nM = 10\n613-317-00-X\npenconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole\n266-275-6\n66246-88-6\nRepr. 2\nAcute Tox. 4\nAquatic Acute 1\nAquatic Chronic 1\nH361d\nH302\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH361d\nH302\nH410\nM = 1\nM = 1\n613-318-00-5\nfenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate\n-\n473798-59-3\nAquatic Chronic 2\nH411\nGHS09\nH411\n616-212-00-7\n3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate\n259-627-5\n55406-53-6\nAcute Tox. 3\nAcute Tox. 4\nSTOT RE 1\nEye Dam. 1\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH331\nH302\nH372 (larynx)\nH318\nH317\nH400\nH410\nGHS06\nGHS08\nGHS05\nGHS09\nDgr\nH331\nH302\nH372 (larynx)\nH318\nH317\nH410\nM = 10\nM = 1\n’\n(2) Table 3.2 is amended as follows:\n(a) the entry corresponding to index number 015-188-00-X is deleted;\n(b) the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 and 616-035-00-5 are replaced by the following corresponding entries:\n‘\n006-086-00-6\nfenoxycarb (ISO);ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate\n276-696-7\n72490-01-8\nCarc. Cat. 3; R40\nN; R50-53\nXn; N\nR: 40-50/53\nS: (2-)22-36/37-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n015-154-00-4\nethephon; 2-chloroethylphosphonic acid\n240-718-3\n16672-87-0\nC; R34\nXn; R20/21/22\nN; R51-53\nC; N\nR: 20/21/22-34-51/53\nS: (1/2-)26-36/37/39-45-61\nXi; R37: 5 % ≤ C < 10 %\n015-192-00-1\ntetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate\n432-770-2\n139189-30-3\nR43\nXi\nR: 43\nS: (2-)24-37\n601-023-00-4\nethylbenzene\n202-849-4\n100-41-4\nF; R11\nXn; R20-48/20-65\nF; Xn\nR: 11-20-48/20-65\nS: (2-)16-24/25-29-62\n601-026-00-0\nstyrene\n202-851-5\n100-42-5\nRepr. Cat. 3; R63\nXn; R20-48/20\nXi; R36/38\nR10\nXn\nR: 10-20-36/38-48/20-63\nS: (2-)23-36/37-46\nXn; R20: C ≥ 12,5 %\nXi; R36/38: C ≥ 12,5 %\nD\n603-061-00-7\ntetrahydro-2-furylmethanol;\ntetrahydrofurfuryl alcohol\n202-625-6\n97-99-4\nRepr. Cat. 2; R61\nRepr. Cat. 3; R62\nXi; R36\nT\nR: 36-61-62\nS: 45-53\nXi; R36: C ≥ 10 %\n605-001-00-5\nformaldehyde …%\n200-001-8\n50-00-0\nCarc. Cat. 2; R45\nMuta. Cat. 3; R68\nT; R23/24/25\nC; R34\nR43\nT\nR: 23/24/25-34-43-45-68\nS: 45-53\nT; R23/24/25: C ≥ 25 %\nXn; R20/21/22: 5 % ≤ C < 25 %\nC; R34: C ≥ 25 %\nXi; R36/37/38: 5 % ≤ C < 25 %\nR43: C ≥ 0,2 %\nB, D\n616-035-00-5\ncymoxanil (ISO);\n2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide\n261-043-0\n57966-95-7\nRepr. Cat. 3; R62-63\nXn; R22-48/22\nR43\nN; R50-53\nXn; N\nR: 22-43-48/22-62-63-50/53\nS: (2-)36/37-46-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n’\n(c) the following entries are inserted in accordance with the order of the entries set out in Table 3.2:\n‘\n050-028-00-2\n2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate\n260-829-0\n57583-35-4\nRepr. Cat. 3; R63\nT; R48/25\nXn; R22\nR43\nT\nR: 22-43-48/25-63\nS: (1/2-)36/37-45\n050-029-00-8\ndimethyltin dichloride\n212-039-2\n753-73-1\nRepr. Cat. 3; R63\nT+; R26\nT; R24/25-48/25\nC; R34\nT+\nR: 24/25-26-34-48/25-63\nS: (1/2-)26-28-36/37/39-45-63\n601-088-00-9\n4-vinylcyclohexene\n202-848-9\n100-40-3\nCarc. Cat. 3; R40\nXn\nR: 40\nS: (2-)36/37\n601-089-00-4\nmuscalure; cis-tricos-9-ene\n248-505-7\n27519-02-4\nR43\nXi\nR: 43\nS: (2-)24-37\n604-090-00-8\n4-tert-butylphenol\n202-679-0\n98-54-4\nRepr. Cat. 3; R62\nXi; R38-41\nXn\nR: 38-41-62\nS: (2-)26-36/37/39-46\n604-091-00-3\netofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether\n407-980-2\n80844-07-1\nR64\nN; R50-53\nN\nR: 50/53-64\nS: 60-61\nN; R50-53: C ≥ 0,25 %\nN; R51-53: 0,025 % ≤ C < 0,25 %\nR52-53: 0,0025 % ≤ C < 0,025 %\n606-146-00-7\ntralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one\n–\n87820-88-0\nCarc. Cat. 3; R40\nXn; R22\nN; R51-53\nXn; N\nR: 22-40-51/53\nS: (2-)36/37-60-61\n606-147-00-2\ncycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one\n405-230-9\n101205-02-1\nF; R11\nRepr. Cat. 3; R63\nF; Xn\nR: 11-63\nS: (2-)16-36/37-46\n607-705-00-8\nbenzoic acid\n200-618-2\n65-85-0\nT; R48/23\nXi; R38-41\nT\nR: 38-41-48/23\nS: (1/2-)26-39-45-63\n607-706-00-3\nmethyl 2,5-dichlorobenzoate\n220-815-7\n2905-69-3\nXn; R22\nN; R51-53\nXn; N\nR: 22-51/53\nS: (2-) 46-61\n612-287-00-5\nfluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine\n-\n79622-59-6\nRepr. Cat. 3; R63\nXn; R20\nXi; R41\nR43\nN; R50-53\nXn; N\nR: 20-41-43-50/53-63\nS: (2-)26-36/37/39-46-60-61\nN; R50-53: C ≥ 2,5 %\nN; R51-53: 0,25 % ≤ C < 2,5 %\nR52-53: 0,025 % ≤ C < 0,25 %\n613-317-00-X\npenconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole\n266-275-6\n66246-88-6\nRepr. Cat. 3; R63\nXn; R22\nN; R50-53\nXn; N\nR: 22-50/53-63\nS: (2-) 36/37-46-60-61\nN; R50-53: C ≥ 25 %\nN; R51-53: 2,5 % ≤ C < 25 %\nR52-53: 0,25 % ≤ C < 2,5 %\n613-318-00-5\nfenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate\n-\n473798-59-3\nN; R51-53\nN\nR: 51/53\nS: 60-61\n616-212-00-7\n3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate\n259-627-5\n55406-53-6\nT; R23-48/23\nXn; R22\nXi; R41\nR43\nN; R50\nT; N\nR: 22-23-41-43-48/23-50\nS: (1/2-)24-26-37/39-45-63\nN; R50: C ≥ 2,5 %\n’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2014/605/annex/III",
    "retrieved_at": "2026-11-01T14:47:35.604818+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}